Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lenalidomide: an immunomodulatory drug.

Edward Crane1, Alan List

  • 1H Lee Moffitt Cancer Center and Research Institute, and the University of South Florida College of Medicine, Malignancy Hematology Program, Department of Interdisciplinary Oncology, Tampa, FL 33612, USA. listAF@moffitt.usf.edu

Future Oncology (London, England)
|March 25, 2006
PubMed
Summary

Lenalidomide, a thalidomide derivative, shows improved potency and a changed side-effect profile. This immunomodulatory drug is investigated for myelodysplastic syndrome, multiple myeloma, and other cancers.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cell cycle arrest: A breakthrough in the supportive care of older cancer patients.

Journal of the American Geriatrics Society·2023
Same author

A Proactive Approach to Prevent Hematopoietic Exhaustion During Cancer Chemotherapy in Older Patients: Temporary Cell-Cycle Arrest.

Drugs & aging·2023
Same author

Correction to: New Advances in Supportive Care: Chemoprotective Agents as Novel Opportunities in Geriatric Oncology.

Current oncology reports·2022
Same author

New Advances in Supportive Care: Chemoprotective Agents as Novel Opportunities in Geriatric Oncology.

Current oncology reports·2022
Same author

The role of innate immunity in MDS pathogenesis.

HemaSphere·2022
Same author

Validation of International Working Group response criteria in higher-risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium.

Cancer medicine·2020

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Lenalidomide is an immunomodulatory drug and a thalidomide derivative.
  • It exhibits improved potency and altered side-effect profile compared to thalidomide.
  • Neurologic toxicity and pro-thrombotic effects are reduced, but caution is advised when combined with dexamethasone.

Purpose of the Study:

  • To review preclinical and clinical data of lenalidomide.
  • To discuss its toxicities and future therapeutic prospects.
  • To highlight its potential in treating various malignancies.

Main Methods:

  • Review of published preclinical and clinical investigation data.
  • Analysis of data presented at the American Society of Clinical Oncology meeting (May 2005).
  • Ongoing clinical trials for various malignancies.

Related Experiment Videos

Main Results:

  • Lenalidomide demonstrates efficacy in myelodysplastic syndrome and multiple myeloma.
  • Further clinical trials are exploring its use in other cancers.
  • The drug's toxicity profile is being continuously evaluated.

Conclusions:

  • Lenalidomide represents a promising therapeutic agent in oncology.
  • Its application extends beyond multiple myeloma and myelodysplastic syndrome.
  • Continued research is essential to fully understand its potential and risks.